Report cover image

Global Anti-obesity Medicine Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published May 17, 2025
Length 192 Pages
SKU # APRC20362036

Description

Summary

According to APO Research, The global Anti-obesity Medicine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Anti-obesity Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Anti-obesity Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Anti-obesity Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Anti-obesity Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Anti-obesity Medicine include Eisai, Novo Nordisk, Merck, Roche, Pfizer, GlaxoSmithKline, Vivus, Orexigen Therapeutics and Boehringer Ingelheim, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Anti-obesity Medicine, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Anti-obesity Medicine, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-obesity Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-obesity Medicine revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Anti-obesity Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Anti-obesity Medicine revenue, projected growth trends, production technology, application and end-user industry.

Anti-obesity Medicine Segment by Company

Eisai
Novo Nordisk
Merck
Roche
Pfizer
GlaxoSmithKline
Vivus
Orexigen Therapeutics
Boehringer Ingelheim
Arena Pharmaceuticals
Amylin Pharmaceuticals
Alizyme
Anti-obesity Medicine Segment by Type

Prescription Drugs
OTC Drugs
Anti-obesity Medicine Segment by Application

Men
Women
Anti-obesity Medicine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-obesity Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-obesity Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-obesity Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Anti-obesity Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Anti-obesity Medicine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-obesity Medicine revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Anti-obesity Medicine Market by Type
1.2.1 Global Anti-obesity Medicine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Prescription Drugs
1.2.3 OTC Drugs
1.3 Anti-obesity Medicine Market by Application
1.3.1 Global Anti-obesity Medicine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Men
1.3.3 Women
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Anti-obesity Medicine Market Dynamics
2.1 Anti-obesity Medicine Industry Trends
2.2 Anti-obesity Medicine Industry Drivers
2.3 Anti-obesity Medicine Industry Opportunities and Challenges
2.4 Anti-obesity Medicine Industry Restraints
3 Global Growth Perspective
3.1 Global Anti-obesity Medicine Market Perspective (2020-2031)
3.2 Global Anti-obesity Medicine Growth Trends by Region
3.2.1 Global Anti-obesity Medicine Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Anti-obesity Medicine Market Size by Region (2020-2025)
3.2.3 Global Anti-obesity Medicine Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Anti-obesity Medicine Revenue by Players
4.1.1 Global Anti-obesity Medicine Revenue by Players (2020-2025)
4.1.2 Global Anti-obesity Medicine Revenue Market Share by Players (2020-2025)
4.1.3 Global Anti-obesity Medicine Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Anti-obesity Medicine Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Anti-obesity Medicine Key Players Headquarters & Area Served
4.4 Global Anti-obesity Medicine Players, Product Type & Application
4.5 Global Anti-obesity Medicine Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Anti-obesity Medicine Market CR5 and HHI
4.6.3 2024 Anti-obesity Medicine Tier 1, Tier 2, and Tier 3
5 Anti-obesity Medicine Market Size by Type
5.1 Global Anti-obesity Medicine Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Anti-obesity Medicine Revenue by Type (2020-2031)
5.3 Global Anti-obesity Medicine Revenue Market Share by Type (2020-2031)
6 Anti-obesity Medicine Market Size by Application
6.1 Global Anti-obesity Medicine Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Anti-obesity Medicine Revenue by Application (2020-2031)
6.3 Global Anti-obesity Medicine Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Eisai
7.1.1 Eisai Comapny Information
7.1.2 Eisai Business Overview
7.1.3 Eisai Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.1.4 Eisai Anti-obesity Medicine Product Portfolio
7.1.5 Eisai Recent Developments
7.2 Novo Nordisk
7.2.1 Novo Nordisk Comapny Information
7.2.2 Novo Nordisk Business Overview
7.2.3 Novo Nordisk Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.2.4 Novo Nordisk Anti-obesity Medicine Product Portfolio
7.2.5 Novo Nordisk Recent Developments
7.3 Merck
7.3.1 Merck Comapny Information
7.3.2 Merck Business Overview
7.3.3 Merck Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.3.4 Merck Anti-obesity Medicine Product Portfolio
7.3.5 Merck Recent Developments
7.4 Roche
7.4.1 Roche Comapny Information
7.4.2 Roche Business Overview
7.4.3 Roche Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.4.4 Roche Anti-obesity Medicine Product Portfolio
7.4.5 Roche Recent Developments
7.5 Pfizer
7.5.1 Pfizer Comapny Information
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.5.4 Pfizer Anti-obesity Medicine Product Portfolio
7.5.5 Pfizer Recent Developments
7.6 GlaxoSmithKline
7.6.1 GlaxoSmithKline Comapny Information
7.6.2 GlaxoSmithKline Business Overview
7.6.3 GlaxoSmithKline Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.6.4 GlaxoSmithKline Anti-obesity Medicine Product Portfolio
7.6.5 GlaxoSmithKline Recent Developments
7.7 Vivus
7.7.1 Vivus Comapny Information
7.7.2 Vivus Business Overview
7.7.3 Vivus Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.7.4 Vivus Anti-obesity Medicine Product Portfolio
7.7.5 Vivus Recent Developments
7.8 Orexigen Therapeutics
7.8.1 Orexigen Therapeutics Comapny Information
7.8.2 Orexigen Therapeutics Business Overview
7.8.3 Orexigen Therapeutics Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.8.4 Orexigen Therapeutics Anti-obesity Medicine Product Portfolio
7.8.5 Orexigen Therapeutics Recent Developments
7.9 Boehringer Ingelheim
7.9.1 Boehringer Ingelheim Comapny Information
7.9.2 Boehringer Ingelheim Business Overview
7.9.3 Boehringer Ingelheim Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.9.4 Boehringer Ingelheim Anti-obesity Medicine Product Portfolio
7.9.5 Boehringer Ingelheim Recent Developments
7.10 Arena Pharmaceuticals
7.10.1 Arena Pharmaceuticals Comapny Information
7.10.2 Arena Pharmaceuticals Business Overview
7.10.3 Arena Pharmaceuticals Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.10.4 Arena Pharmaceuticals Anti-obesity Medicine Product Portfolio
7.10.5 Arena Pharmaceuticals Recent Developments
7.11 Amylin Pharmaceuticals
7.11.1 Amylin Pharmaceuticals Comapny Information
7.11.2 Amylin Pharmaceuticals Business Overview
7.11.3 Amylin Pharmaceuticals Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.11.4 Amylin Pharmaceuticals Anti-obesity Medicine Product Portfolio
7.11.5 Amylin Pharmaceuticals Recent Developments
7.12 Alizyme
7.12.1 Alizyme Comapny Information
7.12.2 Alizyme Business Overview
7.12.3 Alizyme Anti-obesity Medicine Revenue and Gross Margin (2020-2025)
7.12.4 Alizyme Anti-obesity Medicine Product Portfolio
7.12.5 Alizyme Recent Developments
8 North America
8.1 North America Anti-obesity Medicine Revenue (2020-2031)
8.2 North America Anti-obesity Medicine Revenue by Type (2020-2031)
8.2.1 North America Anti-obesity Medicine Revenue by Type (2020-2025)
8.2.2 North America Anti-obesity Medicine Revenue by Type (2026-2031)
8.3 North America Anti-obesity Medicine Revenue Share by Type (2020-2031)
8.4 North America Anti-obesity Medicine Revenue by Application (2020-2031)
8.4.1 North America Anti-obesity Medicine Revenue by Application (2020-2025)
8.4.2 North America Anti-obesity Medicine Revenue by Application (2026-2031)
8.5 North America Anti-obesity Medicine Revenue Share by Application (2020-2031)
8.6 North America Anti-obesity Medicine Revenue by Country
8.6.1 North America Anti-obesity Medicine Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Anti-obesity Medicine Revenue by Country (2020-2025)
8.6.3 North America Anti-obesity Medicine Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Anti-obesity Medicine Revenue (2020-2031)
9.2 Europe Anti-obesity Medicine Revenue by Type (2020-2031)
9.2.1 Europe Anti-obesity Medicine Revenue by Type (2020-2025)
9.2.2 Europe Anti-obesity Medicine Revenue by Type (2026-2031)
9.3 Europe Anti-obesity Medicine Revenue Share by Type (2020-2031)
9.4 Europe Anti-obesity Medicine Revenue by Application (2020-2031)
9.4.1 Europe Anti-obesity Medicine Revenue by Application (2020-2025)
9.4.2 Europe Anti-obesity Medicine Revenue by Application (2026-2031)
9.5 Europe Anti-obesity Medicine Revenue Share by Application (2020-2031)
9.6 Europe Anti-obesity Medicine Revenue by Country
9.6.1 Europe Anti-obesity Medicine Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Anti-obesity Medicine Revenue by Country (2020-2025)
9.6.3 Europe Anti-obesity Medicine Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China Anti-obesity Medicine Revenue (2020-2031)
10.2 China Anti-obesity Medicine Revenue by Type (2020-2031)
10.2.1 China Anti-obesity Medicine Revenue by Type (2020-2025)
10.2.2 China Anti-obesity Medicine Revenue by Type (2026-2031)
10.3 China Anti-obesity Medicine Revenue Share by Type (2020-2031)
10.4 China Anti-obesity Medicine Revenue by Application (2020-2031)
10.4.1 China Anti-obesity Medicine Revenue by Application (2020-2025)
10.4.2 China Anti-obesity Medicine Revenue by Application (2026-2031)
10.5 China Anti-obesity Medicine Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Anti-obesity Medicine Revenue (2020-2031)
11.2 Asia Anti-obesity Medicine Revenue by Type (2020-2031)
11.2.1 Asia Anti-obesity Medicine Revenue by Type (2020-2025)
11.2.2 Asia Anti-obesity Medicine Revenue by Type (2026-2031)
11.3 Asia Anti-obesity Medicine Revenue Share by Type (2020-2031)
11.4 Asia Anti-obesity Medicine Revenue by Application (2020-2031)
11.4.1 Asia Anti-obesity Medicine Revenue by Application (2020-2025)
11.4.2 Asia Anti-obesity Medicine Revenue by Application (2026-2031)
11.5 Asia Anti-obesity Medicine Revenue Share by Application (2020-2031)
11.6 Asia Anti-obesity Medicine Revenue by Country
11.6.1 Asia Anti-obesity Medicine Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Anti-obesity Medicine Revenue by Country (2020-2025)
11.6.3 Asia Anti-obesity Medicine Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Anti-obesity Medicine Revenue (2020-2031)
12.2 SAMEA Anti-obesity Medicine Revenue by Type (2020-2031)
12.2.1 SAMEA Anti-obesity Medicine Revenue by Type (2020-2025)
12.2.2 SAMEA Anti-obesity Medicine Revenue by Type (2026-2031)
12.3 SAMEA Anti-obesity Medicine Revenue Share by Type (2020-2031)
12.4 SAMEA Anti-obesity Medicine Revenue by Application (2020-2031)
12.4.1 SAMEA Anti-obesity Medicine Revenue by Application (2020-2025)
12.4.2 SAMEA Anti-obesity Medicine Revenue by Application (2026-2031)
12.5 SAMEA Anti-obesity Medicine Revenue Share by Application (2020-2031)
12.6 SAMEA Anti-obesity Medicine Revenue by Country
12.6.1 SAMEA Anti-obesity Medicine Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Anti-obesity Medicine Revenue by Country (2020-2025)
12.6.3 SAMEA Anti-obesity Medicine Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.